Vivos Therapeutics (NASDAQ:VVOS) Announces Earnings Results

Vivos Therapeutics (NASDAQ:VVOS) announced its quarterly earnings data on Wednesday. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.07), Zacks reports. Vivos Therapeutics had a negative net margin of 127.70% and a negative return on equity of 1,347.12%. The firm had revenue of $5.14 million during the quarter, compared to the consensus estimate of $4.35 million.

Vivos Therapeutics Stock Performance

NASDAQ:VVOS opened at $0.59 on Friday. Vivos Therapeutics has a 52-week low of $0.55 and a 52-week high of $7.95. The company has a debt-to-equity ratio of 3.31, a quick ratio of 0.24 and a current ratio of 0.24. The firm has a market capitalization of $8.13 million, a PE ratio of -0.28 and a beta of 6.25. The stock has a 50-day simple moving average of $1.03 and a two-hundred day simple moving average of $1.63.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. HC Wainwright decreased their price target on shares of Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating for the company in a research note on Friday, April 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Monday, April 20th. Finally, Ascendiant Capital Markets reduced their price objective on Vivos Therapeutics from $5.50 to $3.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $2.75.

Insider Buying and Selling

In other news, major shareholder Michael C. Skaff purchased 1,353,625 shares of the company’s stock in a transaction on Tuesday, March 31st. The stock was acquired at an average cost of $1.34 per share, for a total transaction of $1,813,857.50. Following the completion of the transaction, the insider directly owned 1,353,625 shares in the company, valued at $1,813,857.50. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Connective Capital Management LLC bought a new position in Vivos Therapeutics in the third quarter worth approximately $620,000. DRW Securities LLC lifted its holdings in Vivos Therapeutics by 179.5% during the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after buying an additional 74,441 shares during the period. B. Riley Wealth Advisors Inc. bought a new stake in Vivos Therapeutics during the 2nd quarter valued at $220,000. Finally, XTX Topco Ltd purchased a new position in shares of Vivos Therapeutics in the 2nd quarter valued at $65,000. 26.35% of the stock is owned by hedge funds and other institutional investors.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.